Market for Impact

Summary

What do they do? PVF funds eye-care access, education/research and the institute. It controls a real-estate entity and holds91% of PVSC LLC in the FY2024 filing. Lions and CPMC partners examine, refer and treat patients. The current charity pathway includes non-cataract care; low-vision rehabilitation and training are not assigned invented QALYs. More

Why this approach interests us

PVF supports a real shared pathway for uninsured people to receive earlier eye care, alongside clinician training and infrastructure.

Our main reservations

Only first-eye earlier-care health is quantified. Marginal allocation, actual earlier access, first-eye case mix and residence are unmeasured. Partner outcomes cannot all be attributed independently to PVF.

What do you get for your dollar?

Our central whole-gift estimate is $7.94M per 10 Bay Area QALYs for the first-eye health component. The entire gift is costed, but health from the remaining 90% of assumed allocation is unquantified—not zero. This is not a complete expected organization return. The earlier $714,286 estimate assumes all donor cash supports selected surgery cases. Inspect the whole-gift model or the historical conditional model.

central ordinary gift /10 qalys: $17.86M SF /$7.94M Bay /$7.14M US — Same full $100,000 cost; health0.056 SF /0.126 Bay /0.14 US.
explicit marginal allocation: 10% first-eye /90% unquantified — Not the990 program ratio. Remaining clinical, educational, building and central spending stays priced.
central resources: $125,000 gross /$100,369 net — Net offsets explicitly assumed otherwise-later outside surgery resources; no claimed general savings.
historical program comparison: $714,286 donor/10 QALYs — All spend on selected SF first-eye courses. Preserved separately; not an ordinary gift price.

1. What do they do?

PVF funds eye-care access, education/research and the institute. It controls a real-estate entity and holds91% of PVSC LLC in the FY2024 filing. Lions and CPMC partners examine, refer and treat patients. The current charity pathway includes non-cataract care; low-vision rehabilitation and training are not assigned invented QALYs.

Allocate the ordinary gift

10% first-eye support;10% other clinical,15% education/research,40% building/capital and25% central/other support. These are explicit priors, not audited shares.

Support unique assigned courses

$10,000 at$1,000/course funds10 nominal first-eye courses;50% financing additionality yields5 added courses. Failed referrals stay within course costing.

Transfer the finite trial contrast

0.056 integrated one-year trial QALY ×50% local clinical/comparator fit; no second eye, extra duration, success multiplier or lifetime blindness avoidance.

Retain partners and regional scope

One shared outcome, outside clinical inputs, real later-care baseline and nested patient-residence priors. SF clinical location alone is insufficient.

Scope of this review. The current patient page specifies uninsured physician-referred Lions patients. Broader impact-report underinsured wording is not assumed to expand core eligibility.

2. Monitoring and information sharing

Mixed clinical access, training and facilities portfolio

Current primary program descriptions and2025 impact report. 2,542 surgeries in2025;570 charity cases cumulative since2020, not all annual first-eye cases.

Our assessment. No division of mixed/cumulative output into annual foundation cost; annual charity first-eye count and residence unknown.

First-eye expedited surgery versus roughly one-year wait

Randomized-assignment economic analysis among288 of306 older women. 0.056 integrated QALY difference;18 missing six-month EQ-5D outcomes excluded.

Our assessment. Utility shape was assumed for the year; no automatic attrition/success multiplier or extra falls effect. Local transfer remains a judgment.

PVF, disregarded property entity and controlled surgery-center interest

Primary990 and related-entity schedule. Internal charity transfer and separate rental netting expose broader financial scope.

Our assessment. Standalone filing is not consolidated clinical revenue, whole resource consumption or marginal allocation.

3. Qualitative assessment

PVF supports a real shared pathway for uninsured people to receive earlier eye care, alongside clinician training and infrastructure.

Key reservations

An ordinary gift cannot inherit100% selected-case allocation or100% SF residency.
Current referrals, clinical suitability, first-eye status and real wait without the gift are unknown.
PVSC/Lions/CPMC outcomes are jointly produced and must not be added again across reports.
The outside clinical cost and otherwise-later offset are both priors, not invoices or payer charges.
No consolidated audit was obtained; the current balance sheet does not identify unrestricted marginal funding room.

Benefits not included in our estimate

Other cataract/second-eye, retina, corneal and glaucoma care
Low-vision rehabilitation and other clinical support
Residency, fellowship, research and professional education
Future facilities and surgery-center sustainability benefits
Fall-related gains already included in trial utility; no separate addition
Health beyond the one-year earlier-care contrast

4. What do you get for your dollar?

Whole-gift cost with a finite, already-integrated first-year health stream

The modeled benefit is earlier first-eye surgery versus otherwise delayed surgery, not permanent denial. The legacy clinical coefficient is unchanged; the revision corrects the donation and geographic scope.

A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.

How we calculate the estimate

Whole gift, finite first-eye assignment effect: Nominal courses = gift × first-eye allocation / direct cash per course. Added courses = nominal × financing additionality. Benefit = added × integrated first-year trial QALY × local clinical/timing transfer. Subtract added-course extra harm and independent gift-date losses. Regional Q = benefit × benefit share − losses × loss share. All price numerators retain the entire gift.
US0.14 /Bay0.126 /SF0.056 QALYs. SF donor/gross/net prices $17,857,143 /$22,321,429 /$17,923,113 per10 QALYs.

Model inputs and assumptions

Whole unrestricted gift: $100,000 (range: Domain $1–$1 billion). Entire ordinary gift retained; no priced restricted offer. Specified gift.
Direct first-eye course allocation: 10% (range: 5–40%; zero). Marginal portfolio prior, not historical charity-care expense ratio. Other90% cost retained. Explicit uncalibrated prior.
Direct cash per assigned unique first-eye course: $1,000 (range: $500–$2,000; $250 unverified sensitivity). Legacy constructed cash budget includes referral/noncompletion costs. Separate portfolio allocation retains central costs; no second-eye benefit. Explicit uncalibrated prior.
Integrated first-year trial QALY effect: 0.056 (range: 0.006 external lower-coordinate stress). Economic randomized-assignment analysis among288/306 with six-month utility extrapolation; not a local observed effect or full-cohort outcome. External integrated economic-trial result; transfer uncertain.
Local clinical/comparator transfer: 50% (range: 12.5–100%; zero; −50% harm). Joint population, severity, actual waiting-time and pathway-fit prior. No permanent-denial or lifetime extension. Explicit uncalibrated prior.
Funding additionality: 50% (range: 25–75%; zero). Added support versus existing PVF/Lions/CPMC/clinical financing; distinct from clinical transfer. Explicit uncalibrated prior.
Extra shared harm per added course: 0 gift-date PV QALY (range: 0.04 stress). Outside complications already incorporated in trial. Costs of failed referrals remain. Explicit uncalibrated prior.
Independent donor harm: 0 gift-date PV QALY (range: 0.2 at zero activity). Independent of additional surgery; no second discount. Explicit uncalibrated prior.
Other displaced care health: 0 gift-date PV QALY (range: 1 at target failure). Distinct lost alternative clinic/resource use; not canceled by zero cataract effect. Explicit uncalibrated prior.
Outside public resources: $0 (range: $500 stress). Narrow uninsured route, not proof of zero public resources throughout organization/partners. Real inputs only, no transfer sum. Explicit uncalibrated prior.
Outside private/partner resources: $2,500 (range: $2,000–$4,000; zero donor-pays case). Clinical/facility/lens inputs beyond direct cash and internal charity transfer. Unpriced prior, not charges. Explicit uncalibrated prior.
Otherwise later outside-care resources: $2,500 (range: $0–$4,000 scenarios). Unpriced offset conditional on later surgery, not permanent denial. No offset to retained whole-gift cash. Explicit uncalibrated prior.
Timing of counterfactual outside cost: 1 year (range: 0.25 short-wait sensitivity). Cost valuation parameter; health remains the already integrated one-year trial transfer. Shorter clinical wait requires separate clinical transfer judgment. Explicit uncalibrated prior.
Continuous resource discount: 3% (range: Domain 0–20%). No extra within-year health discount applied to integrated trial result. Explicit uncalibrated prior.
Other net real resource savings: $0 gift-date dollars (range: $150,000 diagnostic; signed domain). Separate resource savings, not patient welfare or transfers; negative denotes additional cost. Explicit uncalibrated prior.
Bay share of benefit: 90% (range: 70–95%). Unmeasured future residence share, not geography inferred from SF clinic location. Explicit uncalibrated prior.
SF share of benefit: 40% (range: 20–60%; zero). Independent nested residence prior; wider California/Nevada pathway retained. Explicit uncalibrated prior.
Bay share of losses: 90% (range: Nested domain 0–100%). Separate allocation of shared/independent/displaced-alternative harm. Explicit uncalibrated prior.
SF share of losses: 40% (range: Nested domain 0–100%). Can differ from health share; regions never summed. Explicit uncalibrated prior.

The full ordinary gift across18 scenarios

central: SF donor $17,857,143/10 QALYs. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / $22,321,429. Net resources $100,369; net US/Bay/SF prices $7,169,245 / $7,965,828 / $17,923,113. Prices per10 QALYs; signed net-resource diagnostics retained.
favorable_joint: SF donor $496,032/10 QALYs. US/Bay/SF QALYs 3.36 / 3.192 / 2.016. Donor US/Bay/SF $297,619 / $313,283 / $496,032. Gross resources $260,000; gross US/Bay/SF prices $773,810 / $814,536 / $1,289,683. Net resources $103,547; net US/Bay/SF prices $308,174 / $324,394 / $513,624. Prices per10 QALYs; signed net-resource diagnostics retained.
pessimistic_positive: SF donor $2,666,666,667/10 QALYs. US/Bay/SF QALYs 0.001875 / 0.0013125 / 0.000375. Donor US/Bay/SF $533,333,333 / $761,904,762 / $2,666,666,667. Gross resources $110,000; gross US/Bay/SF prices $586,666,667 / $838,095,238 / $2,933,333,333. Net resources $100,074; net US/Bay/SF prices $533,727,393 / $762,467,704 / $2,668,636,964. Prices per10 QALYs; signed net-resource diagnostics retained.
no_quantified_allocation: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs 0 / 0 / 0. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $100,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,000; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
replacement_only: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs 0 / 0 / 0. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,000; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
no_timing_advantage: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs 0 / 0 / 0. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
shorter_wait_transfer: SF donor $71,428,571/10 QALYs. US/Bay/SF QALYs 0.035 / 0.0315 / 0.014. Donor US/Bay/SF $28,571,429 / $31,746,032 / $71,428,571. Gross resources $125,000; gross US/Bay/SF prices $35,714,286 / $39,682,540 / $89,285,714. Net resources $100,093; net US/Bay/SF prices $28,598,114 / $31,775,682 / $71,495,285. Prices per10 QALYs; signed net-resource diagnostics retained.
no_credit_future_resource_offset: SF donor $17,857,143/10 QALYs. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / $22,321,429. Net resources $112,500; net US/Bay/SF prices $8,035,714 / $8,928,571 / $20,089,286. Prices per10 QALYs; signed net-resource diagnostics retained.
additional_public_resources: SF donor $17,857,143/10 QALYs. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $130,000; gross US/Bay/SF prices $9,285,714 / $10,317,460 / $23,214,286. Net resources $102,869; net US/Bay/SF prices $7,347,816 / $8,164,241 / $18,369,541. Prices per10 QALYs; signed net-resource diagnostics retained.
donor_pays_clinical_resources: SF donor $62,500,000/10 QALYs. US/Bay/SF QALYs 0.04 / 0.036 / 0.016. Donor US/Bay/SF $25,000,000 / $27,777,778 / $62,500,000. Gross resources $100,000; gross US/Bay/SF prices $25,000,000 / $27,777,778 / $62,500,000. Net resources $100,000; net US/Bay/SF prices $25,000,000 / $27,777,778 / $62,500,000. Prices per10 QALYs; signed net-resource diagnostics retained.
shared_extra_harm: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs -0.06 / -0.054 / -0.024. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
independent_harm_no_activity: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs -0.2 / -0.18 / -0.08. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $100,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,000; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
target_failure_displaces_alternative: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs -1 / -0.9 / -0.4. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
no_sf_health: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs 0.14 / 0.126 / 0. Donor US/Bay/SF $7,142,857 / $7,936,508 / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices $7,169,245 / $7,965,828 / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
negative_clinical_transfer: SF donor No finite positive-health ratio/10 QALYs. US/Bay/SF QALYs -0.14 / -0.126 / -0.056. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per10 QALYs; signed net-resource diagnostics retained.
low_cash_unverified: SF donor $4,464,286/10 QALYs. US/Bay/SF QALYs 0.56 / 0.504 / 0.224. Donor US/Bay/SF $1,785,714 / $1,984,127 / $4,464,286. Gross resources $200,000; gross US/Bay/SF prices $3,571,429 / $3,968,254 / $8,928,571. Net resources $101,478; net US/Bay/SF prices $1,812,102 / $2,013,447 / $4,530,256. Prices per10 QALYs; signed net-resource diagnostics retained.
zero_outside_resource_scenario: SF donor $17,857,143/10 QALYs. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $100,000; gross US/Bay/SF prices $7,142,857 / $7,936,508 / $17,857,143. Net resources $100,000; net US/Bay/SF prices $7,142,857 / $7,936,508 / $17,857,143. Prices per10 QALYs; signed net-resource diagnostics retained.
net_saving_diagnostic: SF donor $17,857,143/10 QALYs. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / $22,321,429. Net resources $-49,631; net US/Bay/SF prices $-3,545,041 / $-3,938,934 / $-8,862,602. Prices per10 QALYs; signed net-resource diagnostics retained.

Uncertainty. Joint favorable donor price is not a calibrated interval or expected return; no tuning to meet $100,000/10. The trial estimated a first-year difference using baseline/six-month utility, assumed from month1 through11 further months. It excluded18/306 for missing utility. Transfer uncertainty is explicit. This partial-health result does not establish that excluded portfolio programs have zero benefit.

5. Funding and previous grants

No verified ordinary-gift allocation, costed extra surgical cohort or counterfactual queue. The partial-health model does not establish a threshold-passing recommendation.

FY2024 functional expense$2,500,604 omits$4,037,544 rental costs already netted in revenue. The$294,366 charity-care transfer to PVSC is not a second cost on top of its clinical resources. Gross resources count all nominal outside inputs; net counts added outside inputs minus an assumed later-care offset. Restricted assets, property debt, insurance/public baseline, partner capacity and the actual next-gift package remain unresolved.

This review does not establish a verified marginal funding offer or a complete history of grants.

Donate

Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.

6. Sources

What we do. Pacific Vision Foundation. Primary funding body, shared clinical pathway and wider mission.. Published: Undated current page; retrieved: September 8, 2026.
For patients. Pacific Vision Foundation. Primary uninsured eligibility and Lions referral route; narrower than impact report wording.. Published: Undated current page; retrieved: September 8, 2026.
2025 impact report. Pacific Vision Foundation. Primary2025 activities/text; screenshot failed so chart shares/revenue not used. Annual surgery versus cumulative charity counts distinguished.. Published: Announced June 11, 2026; July 2026 PDF path; retrieved: September 8, 2026.
FY2024 Form990. Pacific Vision Foundation; IRS filing hosted by ProPublica. Primary e-file return read; rental expenses netted outside functional expenses. Not an obtained consolidated audit.. Published: November 17, 2025 filing; retrieved: September 8, 2026.
FY2024 related organizations. Pacific Vision Foundation; IRS ScheduleR. Primary SFOC/PVSC ownership and internal charity-care transfer; not independent duplicate resources.. Published: November 17, 2025 filing; retrieved: September 8, 2026.
Cost effectiveness of expedited cataract surgery. First-eye trial economic investigators; British Journal of Ophthalmology. Primary extraction retained from accepted legacy audit; direct current NIH access challenge. Missing18/306 and assumed one-year utility shape retained.. Published: 2007; retrieved: September 8, 2026.
Monthly giving and exact recipient. Pacific Vision Foundation. Primary EIN94-2422439; $250 monthly surgery appeal not a verified one-time complete course quote.. Published: Undated current page; 2026 footer; retrieved: September 8, 2026.
Ways to give. Pacific Vision Foundation. Ordinary recipient; no independently verified cataract-restricted open tranche.. Published: Undated official giving route; retrieved: September 8, 2026.

Annual expenses: years and sources

Average annual expenses (three consecutive fiscal years): $2,480,683. Organization size is separate from the modeled cost-effectiveness of a donation.

Pacific Vision Foundation

Form 990 reported whole-entity expenses; includes program, administration and fundraising costs, but excludes costs netted against revenue.

Calendar years ended December 31. Latest listed original return is 2024. Filing-entity expenses; rental expenses netted outside Form 990 functional expenses are excluded. Not a consolidated total of related entities.